Hashimoto's Thyroiditis: A Naturopathic Guide to Root Causes and Therapeutic Protocols

This article is for educational purposes intended for healthcare practitioners and informed readers. It does not constitute medical advice.

Pathophysiology: Autoimmune Destruction of the Thyroid

Hashimoto's thyroiditis — also termed autoimmune thyroiditis or chronic lymphocytic thyroiditis — is the most prevalent autoimmune condition globally and the leading cause of hypothyroidism in iodine-sufficient populations. Its defining pathological feature is a self-sustaining immune attack on thyroid tissue, mediated by autoreactive T lymphocytes and characterised by production of antibodies against thyroid-specific antigens.

The immunological sequence begins with a breakdown of central and peripheral tolerance to thyroid antigens. Autoreactive CD4+ T helper cells infiltrate the thyroid gland and orchestrate a primarily Th1-polarised immune response. This drives clonal expansion of CD8+ cytotoxic T cells that directly destroy thyroid follicular cells (thyrocytes) via perforin-granzyme-mediated apoptosis and Fas-FasL interactions. Simultaneously, B cells activated by Th1 cytokines — particularly IL-12 and IFN-γ — produce the characteristic autoantibodies: anti-thyroid peroxidase (anti-TPO Ab) and anti-thyroglobulin (anti-Tg Ab), which define the condition diagnostically and serve as proxies for ongoing immune activity.

The histological picture is one of progressive lymphocytic infiltration, lymphoid follicle formation within the gland (germinal centres — a feature distinguishing Hashimoto's from other thyroiditis subtypes), and gradual follicular destruction and fibrosis. Thyroid function follows a predictable trajectory in many patients: an early hyperthyroid phase (Hashitoxicosis) may occur as follicular destruction releases preformed thyroid hormone into circulation; a euthyroid phase of variable duration follows; and ultimately progressive hypothyroidism emerges as functional thyroid tissue is exhausted.

The clinical consequence is impaired synthesis of thyroxine (T4) and triiodothyronine (T3) — the hormones governing cellular metabolic rate across virtually every tissue in the body — producing the characteristic symptom constellation of fatigue, cold intolerance, weight gain, constipation, cognitive slowing, hair loss, and depression.

Why TSH Alone Is Insufficient: The Full Thyroid Panel

Conventional thyroid management frequently limits biochemical assessment to thyroid-stimulating hormone (TSH) alone. While TSH is a sensitive marker of pituitary-thyroid axis feedback, exclusive reliance on it creates several clinically important blind spots that are particularly consequential in Hashimoto's management.

TSH reflects pituitary feedback, not tissue-level thyroid hormone availability. TSH, secreted by the anterior pituitary, rises when pituitary thyrotrophs detect insufficient thyroid hormone stimulation. This feedback loop responds primarily to circulating free T4 — but not directly to cellular T3 availability, peripheral conversion efficiency, reverse T3 accumulation, or the autoimmune process itself. A patient with a TSH in the normal reference range may have significant autoantibody burden, impaired T4-to-T3 peripheral conversion, elevated reverse T3 competing at T3 receptors, or progressive thyroid tissue destruction — none of which is captured by TSH measurement alone.

A complete thyroid panel for Hashimoto's assessment should include:

• Free T4 (fT4): The circulating fraction of thyroxine not bound to carrier proteins, and the direct precursor for peripheral T3 conversion. Low fT4 with normal or elevated TSH confirms primary hypothyroidism.
• Free T3 (fT3): The biologically active thyroid hormone that binds nuclear T3 receptors and drives cellular metabolism. Approximately 80% of circulating T3 derives from peripheral conversion of T4 by iodothyronine deiodinase enzymes. Low fT3 with normal or high fT4 indicates impaired peripheral conversion — a clinically relevant finding invisible to TSH alone.
• Reverse T3 (rT3): T4 can be converted to either active T3 or the metabolically inert reverse T3. Under conditions of chronic stress, systemic inflammation, caloric restriction, selenium deficiency, and elevated cortisol, deiodinase balance shifts toward rT3 production. Elevated rT3 competes with active T3 at cellular receptor sites, producing a functional hypothyroid state despite normal TSH and fT4. The fT3:rT3 ratio provides a clinically useful index of effective thyroid hormone utilisation at the tissue level.
• Anti-TPO antibodies: Thyroid peroxidase is the enzyme responsible for organification of iodine during thyroid hormone synthesis. Anti-TPO antibodies are present in approximately 90–95% of Hashimoto's patients and reflect ongoing immune targeting of the gland. Serial measurement allows objective tracking of autoimmune disease activity and response to therapeutic interventions.
• Anti-Tg antibodies: Anti-thyroglobulin antibodies are present in 60–80% of Hashimoto's patients and are particularly useful in seronegative anti-TPO cases. They respond measurably to dietary interventions including gluten elimination.
• TSH: Still a valuable pituitary feedback marker, interpreted in the context of the complete panel rather than in isolation.

The thyroid panel interpretation framework applied in functional and integrative medicine extends this analysis further, integrating TSH, free hormones, antibody burden, and rT3 into a coherent clinical picture. The relationship between methylation and thyroid hormone conversion is directly relevant here — MTHFR variants and folate-cycle impairment reduce deiodinase enzyme function and can impair T4-to-T3 conversion efficiency, adding a methylation dimension to the assessment of inadequate T3 availability.

Root Cause Framework

The autoimmune process in Hashimoto's does not arise in isolation from the biological environment. Epidemiological, immunological, and mechanistic research has identified multiple environmental and biological drivers that trigger and sustain the autoimmune cascade. Naturopathic management prioritises systematic identification and removal of these upstream drivers rather than management of the downstream hormonal deficit in isolation.

Molecular Mimicry with Gluten

The most clinically significant environmental trigger for Hashimoto's is gluten — specifically the gliadin and glutenin fractions of wheat, rye, and barley. The molecular mimicry hypothesis proposes that immune cross-reactivity between gluten peptides and thyroid-specific antigens sustains or amplifies the autoimmune attack on thyroid tissue by keeping the relevant immune response continuously activated.

Gliadin shares amino acid sequence homology with thyroid peroxidase and thyroglobulin. In genetically susceptible individuals, anti-gliadin immune responses may generate cross-reactive antibodies and T cell responses that target thyroid antigens as a form of immune mistaken identity. The co-occurrence of coeliac disease and Hashimoto's significantly exceeds population base rates, and anti-thyroid antibody titres are elevated in coeliac disease patients compared to healthy controls.

Beyond coeliac disease, non-coeliac gluten sensitivity (NCGS) — immune reactivity to gluten in the absence of villous atrophy — may also contribute to thyroid autoimmune burden through gut barrier disruption and systemic immune activation. Diagnostically, coeliac disease requires IgA anti-tTG, IgA anti-endomysial, and intestinal biopsy confirmation before gluten elimination; NCGS is a clinical diagnosis of exclusion. Both support the therapeutic rationale for a supervised gluten elimination trial in Hashimoto's patients.

Intestinal Permeability and Leaky Gut

Increased intestinal permeability is increasingly recognised not merely as a co-occurring finding in autoimmune disease but as a mechanistic prerequisite for autoimmune initiation. Alessio Fasano's triad model proposes: genetic susceptibility + environmental trigger + intestinal permeability = autoimmune disease. Without the permeability component, environmental triggers cannot adequately access the lamina propria immune compartment that generates pathological autoimmune responses. This triad model generalises beyond the thyroid; the shared upstream drivers are explored in the functional medicine approach to autoimmune disease.

In Hashimoto's, the gut-thyroid axis operates through several reinforcing mechanisms. Tight junction protein disruption — driven by zonulin release, dysbiosis, inflammatory cytokines, and gliadin in susceptible individuals — allows luminal antigens to cross the intestinal epithelium and stimulate subepithelial dendritic cells and MALT-associated lymphocytes. This sustained antigen presentation drives systemic Th1 and Th17 polarisation that amplifies thyroid autoimmunity and sustains elevated antibody titres.

Gut health assessment — including comprehensive stool analysis for dysbiosis and pathogen burden, and intestinal permeability markers (faecal zonulin, urinary lactulose:mannitol ratio) — is therefore an integral component of the Hashimoto's root cause workup, not a peripheral investigation. The evidence and limitations of the permeability concept itself are examined in the article on leaky gut and intestinal permeability.

Iodine Excess: The Autoimmune Amplifier

Iodine occupies a paradoxical position in thyroid biology: essential for thyroid hormone synthesis (iodination of tyrosine residues on thyroglobulin), yet supraphysiological iodine loading is a well-documented trigger and amplifier of autoimmune thyroiditis. In autoimmune-susceptible thyroid tissue, excess iodine increases the immunogenicity of thyroglobulin by promoting iodination of additional tyrosine residues that function as neo-antigens for autoreactive T cells, and may directly stimulate inflammatory pathways in thyrocytes through oxidative mechanisms.

Epidemiological evidence from countries that have introduced mandatory iodine fortification programmes demonstrates consistent increases in autoimmune thyroiditis prevalence following iodisation, supporting the population-level association. In Hashimoto's patients, aggressive iodine supplementation above physiological requirements is contraindicated. Clinicians should audit iodine intake from all sources: supplements, fortified foods, seaweed products (kelp, nori), and iodine-containing medications. Genuine iodine deficiency — confirmed by urinary iodine measurement — still requires correction, but at physiological replacement doses rather than supraphysiological loading.

Environmental Toxins

Halide anions — perchlorate (from agricultural fertilisers and contaminated water), fluoride (water fluoridation and dental products), and bromide (brominated flour, flame retardants, certain medications) — compete with iodide at the sodium-iodide symporter (NIS) in the thyroid. Competitive inhibition of NIS impairs iodide organification and thyroid hormone synthesis, creating a functional iodine deficiency state even with adequate dietary iodine intake.

Heavy metals — mercury in particular — disrupt thyroid hormone receptor binding, impair selenoprotein-dependent deiodinase enzyme function, and have been associated with elevated autoantibody titres in human observational data. In patients with occupational or geographical exposure history, urinary halide profiles and heavy metal panels provide actionable clinical information for reducing the environmental driver component of thyroid autoimmunity.

Viral Triggers: The Role of Epstein-Barr Virus

Epstein-Barr virus (EBV) is the best-studied viral trigger for Hashimoto's thyroiditis. Multiple mechanisms are proposed: EBV infects B cells and can drive polyclonal B cell activation and autoantibody production; EBV-encoded proteins share sequence homology with thyroid antigens (a viral molecular mimicry axis); and EBV reactivation — distinct from primary infection and detectable by elevated EBV IgG VCA, EA-D antibody titres — appears to correlate with Hashimoto's flares in susceptible individuals.

A 2018 study in Clinical Endocrinology found elevated EBV DNA and anti-EBV antibody titres in thyroid tissue from Hashimoto's patients compared to controls with non-autoimmune thyroid pathology, supporting viral persistence in the gland as a mechanistic driver. SARS-CoV-2 has produced a documented wave of new-onset thyroiditis and Hashimoto's exacerbation in the post-acute phase, consistent with the viral trigger framework.

The clinical implication: a history of infectious mononucleosis, known EBV reactivation, or clear onset of Hashimoto's following a viral illness should prompt consideration of antiviral immune support strategies — including optimised vitamin D, zinc, N-acetylcysteine, and antivirally active botanical medicines — as part of the root cause protocol.

The Naturopathic Therapeutic Pyramid

Naturopathic management of Hashimoto's follows a hierarchical therapeutic logic, working from the most fundamental upstream interventions to targeted downstream support. Applying downstream interventions before upstream root causes are addressed consistently produces incomplete and often temporary results.

Level 1 — Remove Triggers

The highest-leverage intervention in Hashimoto's management is systematic identification and removal of autoimmune triggers. In practice, this begins with:

• Strict gluten elimination trial (minimum 3–6 months, with antibody re-testing at completion): The most robustly supported dietary trigger removal strategy. Multiple clinical series report meaningful anti-TPO and anti-Tg antibody reductions following gluten elimination, with the strongest effects in patients with concurrent coeliac or NCGS seropositivity.
• Dairy elimination consideration: Casein molecular mimicry is proposed as a secondary dietary trigger; clinical evidence is weaker than for gluten, but a combined gluten-free and dairy-free trial is reasonable for patients with inadequate response to gluten elimination alone.
• Iodine audit and normalisation: Identify and restrict excessive iodine sources without inducing confirmed deficiency.
• Environmental toxin reduction: Filtered water (to reduce perchlorate, fluoride, and heavy metal exposure), mercury-containing fish moderation, and halide-reducing dietary strategies.
• Viral immune support: In patients with evidence of active or recurrent EBV reactivation, targeted antiviral immune support as described above provides a mechanistically coherent adjunct to the dietary trigger removal phase.

Level 2 — Heal the Gut

Following trigger removal, intestinal barrier repair addresses the permeability component that sustains autoimmune activation by allowing continued antigen translocation. Core gut restoration strategies include:

• Dysbiosis treatment: Targeted antimicrobial botanical medicines (berberine, oregano oil, allicin) or prescription antimicrobials where SIBO or significant pathogenic dysbiosis is confirmed on stool analysis
• Epithelial barrier support: L-glutamine (3–5 g daily) as the primary metabolic fuel for enterocytes; zinc carnosine for tight junction protein stabilisation; bovine colostrum for immunoglobulin-mediated mucosal protection
• Prebiotic and probiotic recolonisation: Diversified dietary fibre to support regulatory T cell (Treg) populations in the gut-associated lymphoid tissue; Lactobacillus and Bifidobacterium species with barrier-supporting evidence
• Anti-inflammatory nutrition: Anti-inflammatory nutrition for autoimmune conditions — particularly EPA and DHA from marine omega-3s — reduces the Th1/Th17 pro-inflammatory drive sustaining autoimmune activity. Marine omega-3 supplementation at 2–4 g EPA+DHA daily is a foundational anti-inflammatory intervention with a strong evidence base and excellent tolerability profile.

Level 3 — Support Immune Regulation

Once triggers are removed and gut integrity is restored, targeted immune modulation addresses the ongoing Th1/Th17 imbalance driving the autoimmune attack on thyroid tissue.

Selenium — the strongest single intervention with RCT evidence

Selenium is an essential trace mineral and co-factor for multiple thyroid-relevant selenoproteins including iodothyronine deiodinases (DIO1, DIO2, DIO3 — the enzymes governing T4 conversion to active T3 or inactive rT3), thioredoxin reductase (antioxidant defence), and glutathione peroxidase (protecting thyrocytes from reactive oxygen species generated during hydrogen peroxide-dependent thyroid hormone synthesis).

The evidence for selenium supplementation in Hashimoto's is the strongest single-nutrient RCT evidence base in the autoimmune thyroid literature. Multiple randomised controlled trials — the 2002 Gärtner study (Journal of Clinical Endocrinology & Metabolism), the 2003 Duntas study (European Journal of Endocrinology), and the larger 2007 Mazokopakis trial (Thyroid) — consistently demonstrate that selenium supplementation at 200 mcg/day as selenomethionine produces statistically significant reductions in anti-TPO antibody titres at 3–6 months compared to placebo. The Gärtner trial reported a 36% mean reduction in anti-TPO Ab levels in the selenium group versus approximately 10% in placebo controls. Anti-Tg Ab reductions are less consistently significant across trials but trend in the same direction.

Mechanistically, selenium reduces TPO antibody titres through multiple pathways: restoring deiodinase function reduces hydrogen peroxide accumulation in thyrocytes (excess H2O2 from the iodination reaction drives oxidative stress that amplifies autoimmunity); selenoprotein P functions as an anti-inflammatory; and adequate selenium supports Treg differentiation that attenuates pathological effector T cell responses.

Dosing: 200 mcg/day of selenomethionine is the dose used in positive RCTs and represents the upper boundary of safe long-term supplementation without risk of selenosis. Monitoring serum selenium or selenoprotein P at baseline and after 3–6 months is advisable for patients on sustained supplementation. Food sources of selenium (Brazil nuts contain approximately 70–90 mcg per nut, though concentration varies widely by soil source) can complement but should not replace measured supplementation in a clinical protocol where precise dosing matters.

Vitamin D

Vitamin D deficiency is consistently more prevalent in Hashimoto's patients than in matched controls across multiple cross-sectional studies, and vitamin D receptor (VDR) polymorphisms associate with Hashimoto's disease susceptibility. Vitamin D3 at doses sufficient to maintain serum 25-OH-D at 100–150 nmol/L supports Treg differentiation, reduces IL-17 (the key Th17 pro-autoimmune cytokine), and inhibits dendritic cell-driven effector T cell activation. Supplementation at 3000–5000 IU daily with 25-OH-D monitoring at 3-monthly intervals is standard practice; co-supplementation with vitamin K2 (100–200 mcg MK-7 form) is routinely added to prevent ectopic calcium deposition associated with higher-dose D3 supplementation.

Zinc

Zinc is a co-factor for thyroid hormone receptor signalling, T cell maturation, thymulin production (the thymic hormone regulating T cell tolerance induction), and multiple antioxidant enzyme systems. Zinc deficiency — common in autoimmune conditions and compounded by poor dietary intake — impairs Treg function and amplifies Th17 responses that sustain autoimmunity. Zinc bisglycinate at 25–30 mg daily with food (to reduce nausea) should be balanced with copper supplementation (1–2 mg daily) to prevent zinc-induced copper depletion in patients on sustained zinc therapy.

Low-Dose Naltrexone (LDN)

LDN — typically 1.5–4.5 mg nightly — has emerged as one of the most clinically promising immune-modulating interventions for autoimmune conditions, including Hashimoto's. Standard naltrexone at 50 mg is an opioid receptor antagonist used in addiction medicine; at low doses, transient overnight receptor blockade triggers a compensatory upregulation of endogenous opioid peptide production (met-enkephalin, beta-endorphin) during the following day. These endogenous opioids bind toll-like receptor 4 (TLR4) on microglia and macrophages, reducing neuroinflammation and systemic inflammatory cytokine production, and exert direct immunomodulatory effects on T and NK cell populations that favour immune tolerance.

Published evidence for LDN specifically in Hashimoto's is primarily observational and case-series level, reflecting the economic barriers to large-scale trials of an off-patent compound rather than a mechanistic shortcoming. In clinical practice, LDN at 1.5–4.5 mg nightly — compounded at specialised pharmacies — is well tolerated (the most common adverse effect is vivid dreams during the first 2–4 weeks of treatment), remarkably safe, and produces meaningful symptomatic improvement in energy, brain fog, and health-related quality of life in a substantial proportion of Hashimoto's patients. Anti-TPO antibody reductions have been documented in observational series. Titration from 1.5 mg upward in 1.5 mg increments every 4 weeks to a maximum of 4.5 mg allows tolerance assessment. LDN is contraindicated within 10–14 days of opioid analgesic use; patients on opioid medications are not candidates.

Myo-Inositol

Myo-inositol — a carbocyclic sugar and intracellular second messenger — has received focused attention as an adjunct in Hashimoto's management following the Nordio and Pajalich (2013) randomised trial demonstrating that combined selenium 83 mcg/day plus myo-inositol 600 mg/day produced superior anti-TPO and anti-Tg antibody reductions compared to selenium alone over 6 months in subclinical hypothyroid patients with autoimmune thyroiditis.

Myo-inositol modulates TSH signalling within thyroid follicular cells — TSH receptor signalling proceeds through the phosphatidylinositol pathway, where myo-inositol is a direct precursor — and may improve thyroid hormone synthesis efficiency at the cellular level independently of the autoimmune process. Myo-inositol also carries independent insulin-sensitising properties relevant for the metabolic co-morbidities (insulin resistance, weight gain, PCOS overlap) common in Hashimoto's populations.

At 600–2000 mg daily, myo-inositol is well tolerated with a benign safety profile. Its documented synergistic benefit with selenium, combined with its mechanistic rationale and excellent tolerability, supports its routine inclusion in comprehensive Hashimoto's naturopathic protocols.

Level 4 — Optimise Thyroid Hormone Conversion

Even with successful immune modulation and reduced antibody burden, many Hashimoto's patients experience residual symptoms attributable to impaired T4-to-T3 peripheral conversion or elevated rT3 accumulation. Optimising conversion at this stage involves:

• Selenium sufficiency (already addressed at Level 3): DIO1 and DIO2 are selenoproteins; selenium repletion is the single most important nutritional determinant of conversion efficiency and is addressed in parallel with the immune modulation phase.
• Iron sufficiency: Iron is a co-factor for thyroid peroxidase and influences deiodinase activity; iron deficiency anaemia — common in menstruating women with Hashimoto's — impairs both thyroid hormone synthesis and peripheral conversion and should be investigated and corrected.
• HPA axis and cortisol management: Elevated cortisol drives DIO3 (converting T4 to inactive rT3) over DIO2 (converting T4 to active T3). Adaptogenic botanical support (ashwagandha at 300–600 mg KSM-66 extract daily, rhodiola rosea at 200–400 mg daily), sleep optimisation, and structured stress reduction address the cortisol-conversion relationship as a therapeutic lever.
• Avoidance of severe caloric restriction: Significant caloric deficit shifts deiodinase balance toward rT3 production as a metabolic conservation mechanism — a common iatrogenic contributor to persistent conversion impairment in patients attempting weight management while managing Hashimoto's.

When Levothyroxine (LT4) Is Necessary

Naturopathic intervention in Hashimoto's is not a substitute for thyroid hormone replacement when biochemical hypothyroidism is confirmed and symptomatic. The decision point for LT4 initiation is guided by:

• TSH consistently above 10 mIU/L regardless of symptom severity (broad clinical guideline consensus)
• TSH above 4–5 mIU/L with significant symptoms in a patient with confirmed Hashimoto's — particularly in the context of pregnancy or when trying to conceive, where even borderline TSH elevations carry foetal risk
• TSH in the upper reference range (2.5–4 mIU/L) with high symptom burden, elevated antibody titres, and a depressed fT3:rT3 ratio — a common clinical scenario where earlier intervention is debated but frequently clinically justified in symptomatic patients

Patients already established on LT4 who remain symptomatic despite normal TSH may benefit from assessment for impaired peripheral conversion, elevated rT3, and the nutritional and adrenal contributors described above. The emerging evidence for combination LT4+LT3 therapy (or desiccated thyroid extract containing both T4 and T3 in natural ratio) in selected patients who fail to achieve symptom resolution on LT4 monotherapy represents an area of ongoing clinical evolution that naturopathic practitioners should facilitate rather than discourage, supporting appropriate medical co-management.

Clinical Summary

Hashimoto's thyroiditis is a chronic autoimmune condition whose full management extends well beyond TSH monitoring and LT4 prescription. The pathophysiological architecture is multifactorial: molecular mimicry with gluten and potentially other dietary and viral antigens, intestinal permeability creating the gateway for sustained immune activation, iodine excess and environmental toxins amplifying the autoimmune process, and viral triggers — particularly EBV — initiating or perpetuating immune dysregulation.

Assessment must include the full thyroid panel — free T4, free T3, reverse T3, anti-TPO Ab, anti-Tg Ab, and TSH — to generate the complete clinical picture that TSH alone systematically obscures.

The naturopathic therapeutic pyramid sequences interventions by mechanistic priority: remove triggers (gluten, excess iodine, environmental toxins, viral amplifiers); restore gut integrity; modulate immune regulation with selenium 200 mcg/day (the strongest RCT evidence base of any single natural intervention), vitamin D3, zinc, LDN, and myo-inositol; and optimise peripheral T4-to-T3 conversion through selenium, iron repletion, HPA axis regulation, and avoidance of caloric restriction. LT4 initiation is supported when biochemical hypothyroidism meets clinical or guideline thresholds, and naturopathic care operates as a complementary and mechanistically coherent layer alongside — not in place of — appropriate hormonal replacement when required.

Key References

• Gärtner R, et al. "Selenium supplementation in patients with autoimmune thyroiditis decreases thyroid peroxidase antibodies concentrations." Journal of Clinical Endocrinology & Metabolism 2002; 87(4):1687–1691.
• Duntas LH, et al. "Effects of a 6-month treatment with selenomethionine in patients with autoimmune thyroiditis." European Journal of Endocrinology 2003; 148(4):389–393.
• Mazokopakis EE, et al. "Effects of 12 months treatment with L-selenomethionine on serum anti-TPO antibody levels in patients with Hashimoto's thyroiditis." Thyroid 2007; 17(7):609–612.
• Nordio M, Pajalich R. "Combined treatment with myo-inositol and selenium ensures euthyroidism in subclinical hypothyroidism patients with autoimmune thyroiditis." Journal of Thyroid Research 2013; 2013:424163.
• Fasano A. "Leaky gut and autoimmune diseases." Clinical Reviews in Allergy & Immunology 2012; 42(1):71–78.
• Ventura A, et al. "Gluten-dependent diabetes-related and thyroid-related autoantibodies in patients with celiac disease." Journal of Pediatrics 2000; 137(2):263–265.
• Tomer Y, Davies TF. "Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function." Endocrine Reviews 2003; 24(5):694–717.
• Ragusa F, et al. "Hashimotos' thyroiditis: epidemiology, pathogenesis, clinic and therapy." Best Practice & Research Clinical Endocrinology & Metabolism 2019; 33(6):101367.